Physician profile
Eric J Luk
NPI 1992125934
$15,445.46
in general payments reported to CMS, 2019-2025
46 companies · $3,157 in 2025
The $3,157 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2021: $142 · 2022: $554 · 2023: $6,139 · 2024: $4,487 · 2025: $3,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,550 · Consulting Fee: $4,400 · Food and Beverage: $3,651 · Travel and Lodging: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,550.00 |
| Consulting Fee | $4,400.00 |
| Food and Beverage | $3,650.83 |
| Travel and Lodging | $1,182.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $6,138.19 | 2022-2023 | |
| Janssen Biotech, INC. | $2,708.03 | 2023-2025 | Rybrevant, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $1,251.65 | 2021-2025 | Imfinzi |
| Caris Mpi, INC. | $1,157.19 | 2025 | Mi Cancer Seek |
| E.R. Squibb & Sons, L.L.C. | $353.90 | 2019-2025 | Opdivo, Krazati |
| Merck Sharp & Dohme LLC | $341.89 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Sobi, INC | $294.88 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $234.19 | 2023-2025 | |
| Celgene Corporation | $214.92 | 2019-2025 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $213.76 | 2024-2025 | Datroway, Enhertu, Injectafer |
| Genentech USA, INC. | $196.74 | 2019-2025 | Venclexta, Itovebi, Tecentriq Hybreza |
| Medtronic USA, INC. | $195.30 | 2019 | |
| Pfizer INC. | $191.55 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $176.80 | 2019-2025 | Libtayo |
| Emd Serono, INC. | $136.13 | 2022-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $131.45 | 2024-2025 | Ojjaara, Blenrep, Zejula |
| Amgen INC. | $128.06 | 2022-2025 | Kyprolis, Blincyto, Lumakras |
| Novo Nordisk INC | $121.23 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.72 | 2024-2025 | Fruzaqla, Ninlaro |
| Incyte Corporation | $114.25 | 2024-2025 | Jakafi, Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $99.99 | 2019 | |
| Beone Medicines USA, INC. | $88.43 | 2025 | Brukinsa, Tevimbra |
| Gilead Sciences, INC. | $78.38 | 2025 | Trodelvy |
| Array Biopharma INC | $75.82 | 2025 | Mektovi, Lorbrena, Braftovi |
| Astellas Pharma US INC | $74.94 | 2021-2025 | Padcev, Vyloy |
| Genzyme Corporation | $68.29 | 2023-2024 | |
| Eisai INC. | $65.63 | 2024-2025 | |
| Abbvie INC. | $52.70 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $34.95 | 2023-2024 | Xpovio |
| Dendreon Pharmaceuticals LLC | $32.89 | 2025 | Provenge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.78 | 2024 | Gilotrif |
| Alexion Pharmaceuticals, INC. | $28.00 | 2024 | Ultomiris |
| Seagen INC. | $27.34 | 2023 | Adcetris |
| Geron Corporation | $25.57 | 2025 | Rytelo |
| Mirati Therapeutics, INC. | $23.66 | 2024 | Krazati |
| Stemline Therapeutics INC. | $23.33 | 2023 | Orserdu |
| Jazz Pharmaceuticals INC. | $22.25 | 2025 | |
| Genmab U.S., INC. | $22.18 | 2024 | Epkinly |
| Pharmaessentia USA Corporation | $21.95 | 2025 | Besremi |
| Lilly USA, LLC | $20.78 | 2025 | Jaypirca, Verzenio |
| Agios Pharmaceuticals, INC. | $19.90 | 2023 | Pyrukynd |
| Syndax Pharmaceuticals, INC. | $18.92 | 2025 | |
| Adc Therapeutics America, INC. | $18.49 | 2024 | |
| Pharmacosmos Therapeutics INC. | $18.06 | 2025 | Monoferric |
| Heron Therapeutics, INC. | $15.66 | 2023 | Sustol |
| Apellis Pharmaceuticals, INC. | $14.74 | 2024 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Luk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.